Surveyor Capital logo

Surveyor Capital

North America, Illinois, United States, Chicago

Description

Surveyor Capital is an investment firm that focuses on access and opportunity to companies and entrepreneurs.

Investor Profile

Surveyor Capital has backed more than 152 startups, with 8 new investments in the last 12 months alone. The firm has led 15 rounds, about 10% of its total and boasts 89 exits across its portfolio.

Investment Focus Highlights

  • Concentrates on Series B, Post Ipo Equity, Series C rounds (top funding stages).
  • Majority of deals are located in United States, Switzerland, Canada.
  • Strong thematic focus on Biotechnology, Health Care, Therapeutics.
  • Led 1 rounds in the past year.

Stage Focus

  • Series B (39%)
  • Post Ipo Equity (24%)
  • Series C (18%)
  • Series A (10%)
  • Series Unknown (4%)
  • Series D (3%)
  • Series E (1%)
  • Private Equity (1%)
  • Convertible Note (1%)

Country Focus

  • United States (89%)
  • Switzerland (3%)
  • Canada (2%)
  • United Kingdom (2%)
  • China (1%)
  • Ireland (1%)
  • Germany (1%)
  • Singapore (1%)
  • Denmark (1%)

Industry Focus

  • Biotechnology
  • Health Care
  • Therapeutics
  • Pharmaceutical
  • Medical
  • Biopharma
  • Life Science
  • Oncology
  • Health Diagnostics
  • Precision Medicine
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Surveyor Capital frequently co-invest with?

EcoR1 Capital
North America, California, United States, San Francisco
Co-Investments: 19
OrbiMed
North America, New York, United States, New York
Co-Investments: 35
Wellington Management
North America, Massachusetts, United States, Boston
Co-Investments: 23
CA
North America, Massachusetts, United States, Boston
Co-Investments: 43
Samsara BioCapital
North America, California, United States, Palo Alto
Co-Investments: 27
Biotechnology Value Fund
North America, California, United States, San Francisco
Co-Investments: 21
RA Capital Management
North America, Massachusetts, United States, Boston
Co-Investments: 49
Perceptive Advisors
North America, New York, United States, New York
Co-Investments: 30
Logos Capital
North America, California, United States, San Francisco
Co-Investments: 57
Janus Henderson Investors
Europe, England, United Kingdom, London
Co-Investments: 38

Which angels does Surveyor Capital often collaborate with?

SK
North America, California, United States, Los Angeles
Shared Deals: 1
TA
North America, Massachusetts, United States, Cambridge
Shared Deals: 1
RK
North America, California, United States, Los Angeles
Shared Deals: 1

What are some of recent deals done by Surveyor Capital?

VeraDermics

New Haven, Connecticut, United States

VeraDermics is a dermatology company that creates novel drug delivery mechanisms for a pain-free cure for skin conditions.

Health CarePharmaceuticalTherapeutics
Series COct 16, 2025
Amount Raised: $150,000,000
Adcytherix

Marseille, Provence-Alpes-Cote d'Azur, France

Adcytherix is a biopharmaceutical firm that specializes in the development of new antibody drug conjugates (ADC).

BiotechnologyOncology
Series AOct 16, 2025
Amount Raised: $122,438,699
Kailera Therapeutics

Waltham, Massachusetts, United States

Kailera Therapeutics develops next-generation injectable and oral therapies for chronic weight management.

BiotechnologyPharmaceuticalTherapeutics
Series BOct 14, 2025
Amount Raised: $600,000,000
Oruka Therapeutics

Waltham, Massachusetts, United States

Oruka Therapeutics is advancing innovative biologics to redefine patient care standards in chronic skin diseases.

BiotechnologyHealth CareMedical
Post Ipo EquitySep 17, 2025
Amount Raised: $180,000,000
Avenzo Therapeutics

San Diego, California, United States

Avenzo Therapeutics specializes in the development of oncology therapies for cancer treatment.

BiotechnologyHealth CareMedicalOncologyTherapeutics
Series BSep 4, 2025
Amount Raised: $60,000,000
BBOT

Palo Alto, California, United States

BBOT is a clinical-stage biopharmaceutical company advancing a pipeline of novel therapeutics targeting RAS and PI3Kα malignancies.

BiopharmaTherapeutics
Post Ipo EquityAug 11, 2025
Amount Raised: $261,000,000
Avalyn Pharma

Seattle, Washington, United States

Avalyn Pharma is a biopharma company developing therapies for the treatment of idiopathic pulmonary fibrosis and other respiratory diseases.

BiopharmaBiotechnologyMedicalPharmaceutical
Series DJul 22, 2025
Amount Raised: $100,000,000
Actithera

Oslo, Oslo, Norway

Actithera is a molecular radiotherapeutic company that develops radioligand therapies.

BiotechnologyHealth CareLife ScienceMedicalTherapeutics
Series AJul 9, 2025
Amount Raised: $75,500,000
LEXEO Therapeutics

New York, New York, United States

LEXEO Therapeutics utilizes gene therapy to treat genetically defined cardiovascular and central nervous system diseases.

BiotechnologyLife ScienceTherapeutics
Post Ipo EquityMay 27, 2025
Amount Raised: $80,000,000
Arbor Biotechnologies

Cambridge, Massachusetts, United States

Arbor Biotechnologies is a biotechnology company specializing in next-generation gene editing therapeutics to treat genetic diseases.

BiopharmaBiotechnologyLife Science
Series CMar 18, 2025
Amount Raised: $73,900,000